8-K: CytoSorbents Regains Nasdaq Bid Price Compliance

CytoSorbents Corporation announced it has regained compliance with the Nasdaq minimum bid price requirement, a positive step while still addressing market value concerns.

Summary

• CytoSorbents Corporation has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement of $1.00 per share.
• This compliance was achieved after the closing bid price of the company's common stock was $1.00 or greater for 10 consecutive trading sessions, ending September 21, 2026.
• The company is actively working to address the Market Value of Listed Securities (MVLS) requirement, with a compliance deadline of December 28, 2026.
• To meet the MVLS requirement, the market value of listed securities must be at least $35 million for 10 consecutive business days.
• Alternative options to regain compliance include increasing stockholders' equity to at least $2.5 million.
• The company remains focused on core business objectives including driving sales of CytoSorb, achieving operating cash flow breakeven in the second half of 2026, and advancing DrugSorb-ATR toward FDA approval.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as regaining compliance with Nasdaq's minimum bid price requirement is a crucial step for continued listing, though the company still faces challenges with market value of listed securities.

Positives

• Regained compliance with Nasdaq's minimum bid price requirement ($1.00 per share) for continued listing.
• The matter of the minimum bid price compliance is now closed by Nasdaq.
• The company is actively pursuing strategies to regain compliance with the Market Value of Listed Securities (MVLS) requirement.
• Management is focused on core business objectives such as increasing CytoSorb sales and advancing DrugSorb-ATR.
• Targeting operating cash flow breakeven in the second half of 2026.

Negatives

• The company is still not in compliance with the Nasdaq Market Value of Listed Securities (MVLS) requirement of $35 million.
• There is a risk of delisting if compliance with the MVLS requirement is not achieved by December 28, 2026.
• There can be no assurance that the company will successfully maintain its listing on the Nasdaq Capital Market.

Risks

• Failure to regain compliance with the Market Value of Listed Securities (MVLS) requirement by December 28, 2026, could lead to delisting.
• Potential delisting from the Nasdaq Capital Market.
• The company may not be successful in maintaining its listing on the Nasdaq Capital Market.
• Factors that could cause actual results to differ materially from forward-looking statements include the ability to obtain FDA and Health Canada marketing authorization, reduce costs, optimize operations, and finance the company.

Future Outlook

The company is focused on achieving operating cash flow breakeven in the second half of 2026, advancing DrugSorb-ATR toward FDA regulatory approval, and unlocking the strategic value of assets like HemoDefend-BGA. There is no assurance of maintaining Nasdaq listing.

Management Comments

• "We are pleased to confirm that CytoSorbents has regained compliance with Nasdaq's minimum bid price requirement."
• "In addition, we are working towards full compliance with Nasdaq's Capital Market listing requirements by addressing the minimum Market Value of Listed Securities requirement under Nasdaq Listing Rule 5550(b)(2), or satisfying other alternative options, before the December 28, 2026 compliance date."
• "These efforts are among the key priorities we are systematically addressing as we work to strengthen the Company and build greater visibility and confidence among our shareholders."
• "At the same time, we remain intensely focused on executing our core business objectives: driving sales of CytoSorb, achieving operating cash flow breakeven in the second half of this year, advancing DrugSorb-ATR toward FDA regulatory approval, and unlocking the strategic value of assets such as HemoDefend-BGA."
• "We believe continued execution against these priorities will position CytoSorbents for stronger, sustainable growth and long-term shareholder value."

Industry Context

StockSavvy.ai notes that maintaining a listing on major exchanges like Nasdaq is critical for investor confidence and access to capital. Companies in the medical device sector, particularly those with innovative but not yet widely adopted technologies, often face challenges with market valuation and regulatory hurdles.

Stakeholder Impact

• Shareholders: Potential for continued listing on Nasdaq, which is generally positive for liquidity and investor confidence. However, the ongoing MVLS issue and risk of delisting create uncertainty.
• Creditors: Continued listing on Nasdaq may provide greater stability and access to potential future financing.
• Employees: Maintaining Nasdaq listing can contribute to employee morale and retention.

Next Steps

• Continue to monitor the market value of listed securities to regain compliance with the MVLS requirement.
• Evaluate potential actions to regain compliance with the MVLS requirement.
• Consider other options to regain compliance with Nasdaq's continued listing standards, including increasing stockholders' equity to at least $2.5 million.
• Advance DrugSorb-ATR toward FDA regulatory approval.
• Drive sales of CytoSorb.
• Achieve operating cash flow breakeven in the second half of 2026.

Key Dates

Recommendation

The company has successfully addressed the minimum bid price issue, which is a positive step. However, the ongoing challenge with the Market Value of Listed Securities (MVLS) and the looming December 28, 2026 deadline introduce significant risk. While core business objectives are being pursued, the uncertainty surrounding Nasdaq listing warrants a cautious 'hold' recommendation until compliance with MVLS is more certain or alternative strategies are clearly defined and progressing.

Keywords

CytoSorbents, Nasdaq Compliance, Minimum Bid Price, Market Value of Listed Securities, Blood Purification, DrugSorb-ATR, FDA Approval, Critical Care